SGLT2 inhibition in heart failure with reduced or preserved ejection fraction: Finding the right patients to treat - Université de Lorraine Access content directly
Journal Articles Journal of Internal Medicine Year : 2023

SGLT2 inhibition in heart failure with reduced or preserved ejection fraction: Finding the right patients to treat

Abstract

Sodium-glucose transport inhibitors (SGLT2i) are effective in heart failure (HF) with ejection fraction (EF) <40% (referred to as HF with reduced EF - HFrEF) and left ventricular EF (LVEF) >40%. Current evidence suggests that SGLT2i should be initiated across a large spectrum of EFs and renal function in patients with HF and with and without diabetes. We reviewed the benefits of SGLT2i in the entire spectrum of HF and provided some clues that may guide physicians in their strategy of initiating and maintaining SGLT2i (with or without SGLT1i effect) therapy. Taken together, the evidence thus far arises from an array of trials performed in different settings (acute/chronic), risk categories, and phenotypes of HF (HFrEF/HFpEF), and in addition to the most common HF therapies, supports the homogenous effect of SGLT2i across a large spectrum of patients with HF. SGLT2i appear to be effective and well-tolerated drugs in the majority of clinical HF scenarios, regardless of LVEF, estimated glomerular filtration rate, diabetic status or the level of the acuteness of the clinical setting. Therefore, most patients with HF should be treated with SGLT2i. However, in the face of the therapeutic inertia that has been observed in HF over the past decades, the actual implementation of SGLT2i in routine practice remains the most significant challenge.
Fichier principal
Vignette du fichier
Journal of Internal Medicine - 2023 - Girerd - SGLT2 inhibition in heart failure with reduced or preserved ejection.pdf (573.52 Ko) Télécharger le fichier
Origin Files produced by the author(s)
Licence

Dates and versions

hal-04023839 , version 1 (10-03-2023)

Licence

Identifiers

Cite

Nicolas Girerd, Faiez Zannad. SGLT2 inhibition in heart failure with reduced or preserved ejection fraction: Finding the right patients to treat. Journal of Internal Medicine, In press, 293 (5), pp.550-558. ⟨10.1111/joim.13620⟩. ⟨hal-04023839⟩
15 View
39 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More